Human T cell glycosylation and implications on immune therapy for cancer

References

• Cook KM, Hogg PJ. Post-translational control of protein function by disulfide bond cleavage. Antioxid Redox Signal. 2012;18:1987–2015. doi:10.1089/ars.2012.4807.
   Web of Science ®Google Scholar
• Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J. Molecular cell biology. 4th ed. New York, NY: W. H. Freeman; 2000. Section 17.6, Post-Translational Modifications and Quality Control in the Rough ER. Available from: https://www.ncbi.nlm.nih.gov/books/NBK21741/
   Google Scholar
• Rogers LD, Overall CM. Proteolytic post-translational modification of proteins: proteomic tools and methodology. Mol Cell Proteomics MCP. 2013;12:3532–42. doi:10.1074/mcp.M113.031310.
   PubMed Web of Science ®Google Scholar
• Moremen KW, Tiemeyer M, Nairn AV. Vertebrate protein glycosylation: diversity, synthesis and function. Nat Rev Mol Cell Biol. 2012;13:448–62. doi:10.1038/nrm3383.
   PubMed Web of Science ®Google Scholar
• Neelamegham S, Mahal LK. Multi-level regulation of cellular glycosylation: from genes to transcript to enzyme to structure. Curr Opin Struct Biol. 2016;40:145–52. doi:10.1016/j.sbi.2016.09.013.
   PubMed Web of Science ®Google Scholar
• Pothukuchi P, Agliarulo I, Russo D, Rizzo R, Russo F, Parashuraman S. Translation of genome to glycome: role of the Golgi apparatus. FEBS Lett. 2019;593:2390–411. doi:10.1002/feb2.v593.17.
   PubMed Web of Science ®Google Scholar
• De Wachter C, Van Landuyt L, Callewaert N. Engineering of yeast glycoprotein expression. In: Advances in Biochemical Engineering/Biotechnology. Berlin, Heidelberg: Springer; 2018. p. 1–43. https://link.springer.com/chapter/10.1007/10_2018_69
   Google Scholar
• Nairn AV, York WS, Harris K, Hall EM, Pierce JM, Moremen KW. Regulation of glycan structures in animal tissues. J Biol Chem. 2008;283:17298–313. doi:10.1074/jbc.M801964200.
   PubMed Web of Science ®Google Scholar
• Nairn AV, Aoki K, Dela Rosa M, Porterfield M, Lim J-M, Kulik M, Pierce JM, Wells L, Dalton S, Tiemeyer M, et al. Regulation of glycan structures in murine embryonic stem cells. J Biol Chem. 2012;287:37835–56. doi:10.1074/jbc.M112.405233.
   PubMed Web of Science ®Google Scholar
• Spahn PN, Lewis NE. Systems glycobiology for glycoengineering. Curr Opin Biotechnol. 2014;30:218–24. doi:10.1016/j.copbio.2014.08.004.
   PubMed Web of Science ®Google Scholar
• Liu G, Neelamegham S. Integration of systems glycobiology with bioinformatics toolboxes, glycoinformatics resources, and glycoproteomics data. Wiley Interdiscip Rev Syst Biol Med. 2015;7:163–81. doi:10.1002/wsbm.2015.7.issue-4.
   PubMed Web of Science ®Google Scholar
• Varki A. Biological roles of glycans. Glycobiology. 2017;27:3–49.
   PubMed Web of Science ®Google Scholar
• Baum LG, Cobb BA. The direct and indirect effects of glycans on immune function. Glycobiology. 2017;27:619–24. doi:10.1093/glycob/cwx036.
   PubMed Web of Science ®Google Scholar
• Thiemann S, Baum LG. Galectins and immune responses-just how do they do those things they do? Annu Rev Immunol. 2016;34:243–64. doi:10.1146/annurev-immunol-041015-055402.
   PubMed Web of Science ®Google Scholar
• Horlacher T, Oberli MA, Werz DB, Kröck L, Bufali S, Mishra R, Sobek J, Simons K, Hirashima M, Niki T, et al. Determination of carbohydrate-binding preferences of human galectins with carbohydrate microarrays. Chembiochem Eur J Chem Biol. 2010;11:1563–73. doi:10.1002/cbic.v11:11.
   PubMed Web of Science ®Google Scholar
• Starr TK, Daniels MA, Lucido MM, Jameson SC, Hogquist KA. Thymocyte sensitivity and supramolecular activation cluster formation are developmentally regulated: a partial role for sialylation. J Immunol. 2003;171:4512–20. doi:10.4049/jimmunol.171.9.4512.
   PubMed Web of Science ®Google Scholar
• Cummings RD. Structure and function of the selectin ligand PSGL-1. Braz J Med Biol Res Rev Bras Pesqui Medicas E Biol. 1999;32:519–28. doi:10.1590/S0100-879X1999000500004.
   PubMed Web of Science ®Google Scholar
• Homeister JW, Thall AD, Petryniak B, Malý P, Rogers CE, Smith PL, Kelly RJ, Gersten KM, Askari SW, Cheng G, et al. The alpha(1,3)fucosyltransferases FucT-IV and FucT-VII exert collaborative control over selectin-dependent leukocyte recruitment and lymphocyte homing. Immunity. 2001;15:115–26. doi:10.1016/S1074-7613(01)00166-2.
   PubMed Web of Science ®Google Scholar
• Sperandio M, Frommhold D, Babushkina I, Ellies LG, Olson TS, Smith ML, Fritzsching B, Pauly E, Smith DF, Nobiling R, et al. Alpha 2,3-sialyltransferase-IV is essential for L-selectin ligand function in inflammation. Eur J Immunol. 2006;36:3207–15. doi:10.1002/eji.200636157.
   PubMed Web of Science ®Google Scholar
• Pillai S, Netravali IA, Cariappa A, Mattoo H. Siglecs and immune regulation. Annu Rev Immunol. 2012;30:357–92. doi:10.1146/annurev-immunol-020711-075018.
   PubMed Web of Science ®Google Scholar
• Swamy M, Pathak S, Grzes KM, Damerow S, Sinclair LV, van Aalten DMF, Cantrell DA. Glucose and glutamine fuel protein O-GlcNAcylation to control T cell self-renewal and malignancy. Nat Immunol. 2016;17:712–20. doi:10.1038/ni.3439.
   PubMed Web of Science ®Google Scholar
• Hewagama A, Gorelik G, Patel D, Liyanarachchi P, McCune WJ, Somers E, Gonzalez-Rivera T, Strickland F, Richardson B. Overexpression of X-Linked genes in T cells from women with lupus. J Autoimmun. 2013;41:60–71. doi:10.1016/j.jaut.2012.12.006.
   PubMed Web of Science ®Google Scholar
• Baum LG, Derbin K, Perillo NL, Wu T, Pang M, Uittenbogaart C. Characterization of terminal sialic acid linkages on human thymocytes. J Biol Chem. 1996;271:10793–99. doi:10.1074/jbc.271.18.10793.
   PubMed Web of Science ®Google Scholar
• Martin LT, Marth JD, Varki A, Varki NM. Genetically altered mice with different sialyltransferase deficiencies show tissue-specific alterations in sialylation and sialic acid 9-O-acetylation. J Biol Chem. 2002;277:32930–38. doi:10.1074/jbc.M203362200.
   PubMed Web of Science ®Google Scholar
• Moody AM, Chui D, Reche PA, Priatel JJ, Marth JD, Reinherz EL. Developmentally regulated glycosylation of the CD8αβ coreceptor stalk modulates ligand binding. Cell. 2001;107:501–12. doi:10.1016/S0092-8674(01)00577-3.
   PubMed Web of Science ®Google Scholar
• Daniels MA, Devine L, Miller JD, Moser JM, Lukacher AE, Altman JD, Kavathas P, Hogquist KA, Jameson SC. CD8 binding to MHC class I molecules is influenced by T cell maturation and glycosylation. Immunity. 2001;15:1051–61. doi:10.1016/S1074-7613(01)00252-7.
   PubMed Web of Science ®Google Scholar
• Moody AM, North SJ, Reinhold B, Dyken SJV, Rogers ME, Panico M, Dell A, Morris HR, Marth JD, Reinherz EL. Sialic acid capping of CD8β core 1-O-glycans controls thymocyte-major histocompatibility complex class I interaction. J Biol Chem. 2003;278:7240–46. doi:10.1074/jbc.M210468200.
   PubMed Web of Science ®Google Scholar
• Pappu BP, Shrikant PA. Alteration of cell surface sialylation regulates antigen-induced naive CD8+ T cell responses. J Immunol. 2004;173:275–84. doi:10.4049/jimmunol.173.1.275.
   PubMed Web of Science ®Google Scholar
• Hobbs SJ, Nolz J. Regulation of T cell trafficking by enzymatic synthesis of O-glycans. Front Immunol. 2017;8:600. doi:10.3389/fimmu.2017.00600.
   PubMed Web of Science ®Google Scholar
• Aguilar AL, Gao Y, Hou X, Lauvau G, Yates JR, Wu P. Profiling of protein O-GlcNAcylation in murine CD8+ effector- and memory-like T cells. ACS Chem Biol. 2017;12:3031–38. doi:10.1021/acschembio.7b00869.
   PubMed Web of Science ®Google Scholar
• Dennis JW, Lau KS, Demetriou M, Nabi IR. Adaptive regulation at the cell surface by N-Glycosylation. Traffic. 2009;10:1569–78. doi:10.1111/tra.2009.10.issue-11.
   PubMed Web of Science ®Google Scholar
• Earl LA, Bi S, Baum LG. N- and O-Glycans Modulate Galectin-1 Binding, CD45 Signaling, and T Cell Death. J Biol Chem. 2010;285:2232–44. doi:10.1074/jbc.M109.066191.
   PubMed Web of Science ®Google Scholar
• Morgan R, Gao G, Pawling J, Dennis JW, Demetriou M, Li B. N-acetylglucosaminyltransferase V (Mgat5)-mediated N-glycosylation negatively regulates Th1 cytokine production by T cells. J Immunol Baltim Md 1950. 2004;173:7200–08.
   Google Scholar
• Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M, Dennis JW. Complex N-Glycan Number and Degree of Branching Cooperate to Regulate Cell Proliferation and Differentiation. Cell. 2007;129:123–34. doi:10.1016/j.cell.2007.01.049.
   PubMed Web of Science ®Google Scholar
• Grigorian A, Torossian S, Demetriou M. T-cell growth, cell surface organization, and the galectin glycoprotein lattice. Immunol Rev. 2009;230:232–46. doi:10.1111/imr.2009.230.issue-1.
   PubMed Web of Science ®Google Scholar
• Chen H-L, Li CF, Grigorian A, Tian W, Demetriou M. T cell receptor signaling co-regulates multiple golgi genes to enhance N-glycan branching. J Biol Chem. 2009;284:32454–61. doi:10.1074/jbc.M109.023630.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wearsch PA, Zhu Y, Leonhardt RM, Cresswell P. A role for UDP-glucose glycoprotein glucosyltransferase in expression and quality control of MHC class I molecules. Proc Natl Acad Sci U S A. 2011;108:4956–61. doi:10.1073/pnas.1102527108.
   PubMed Web of Science ®Google Scholar
• Wearsch PA, Peaper DR, Cresswell P. Essential glycan-dependent interactions optimize MHC class I peptide loading. Proc Natl Acad Sci. 2011;108:4950–55. doi:10.1073/pnas.1102524108.
   PubMed Web of Science ®Google Scholar
• Ryan SO, Cobb BA. Host glycans and antigen presentation. Microbes Infect Inst Pasteur. 2012;14:894–903. doi:10.1016/j.micinf.2012.04.010.
   PubMed Web of Science ®Google Scholar
• Ryan SO, Cobb BA. Roles for major histocompatibility complex glycosylation in immune function. Semin Immunopathol. 2012;34:425–41. doi:10.1007/s00281-012-0309-9.
   PubMed Web of Science ®Google Scholar
• Swiedler SJ, Freed JH, Tarentino AL, Plummer TH, Hart GW. Oligosaccharide microheterogeneity of the murine major histocompatibility antigens. Reproducible site-specific patterns of sialylation and branching in asparagine-linked oligosaccharides. J Biol Chem. 1985;260:4046–54.
   PubMed Web of Science ®Google Scholar
• Ryan SO, Bonomo JA, Zhao F, Cobb BA. MHCII glycosylation modulates Bacteroides fragilis carbohydrate antigen presentation. J Exp Med. 2011;208:1041–53. doi:10.1084/jem.20100508.
   PubMed Web of Science ®Google Scholar
• Cobb BA, Kasper DL. Characteristics of carbohydrate antigen binding to the presentation protein HLA-DR. Glycobiology. 2008;18:707–18. doi:10.1093/glycob/cwn050.
   PubMed Web of Science ®Google Scholar
• Johnson JL, Jones MB, Ryan SO, Cobb BA. The Regulatory Power of Glycans and their Binding Partners in Immunity. Trends Immunol. 2013;34:290–98. doi:10.1016/j.it.2013.01.006.
   PubMed Web of Science ®Google Scholar
• Amano M, Galvan M, He J, Baum LG. The ST6Gal I Sialyltransferase selectively modifiesN-Glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death. J Biol Chem. 2003;278:7469–75. doi:10.1074/jbc.M209595200.
   PubMed Web of Science ®Google Scholar
• Araujo L, Khim P, Mkhikian H, Mortales C-L, Demetriou M. Glycolysis and glutaminolysis cooperatively control T cell function by limiting metabolite supply to N-glycosylation. eLife. 2017;6. doi:10.7554/eLife.21330.
   Web of Science ®Google Scholar
• Hauser MA, Kindinger I, Laufer JM, Späte A-K, Bucher D, Vanes SL, Krueger WA, Wittmann V, Legler DF. Distinct CCR7 glycosylation pattern shapes receptor signaling and endocytosis to modulate chemotactic responses. J Leukoc Biol. 2016;99:993–1007. doi:10.1189/jlb.2VMA0915-432RR.
   PubMed Web of Science ®Google Scholar
• Rossi FMV, Corbel SY, Merzaban JS, Carlow DA, Gossens K, Duenas J, So L, Yi L, Ziltener HJ. Recruitment of adult thymic progenitors is regulated by P-selectin and its ligand PSGL-1. Nat Immunol. 2005;6:626–34. doi:10.1038/ni1203.
   PubMed Web of Science ®Google Scholar
• Sultana DA, Zhang SL, Todd SP, Bhandoola A. Expression of functional PSGL-1 on hematopoietic progenitors is developmentally regulated. J Immunol Baltim Md 1950. 2012;188:4385–93.
   Google Scholar
• Li Y, Xie M, Men L, Du J. O-GlcNAcylation in immunity and inflammation: an intricate system (Review). Int J Mol Med. 2019;44:363–74. doi:10.3892/ijmm.2019.4238.
   PubMed Web of Science ®Google Scholar
• Daniels MA, Hogquist KA, Jameson SC. Sweet “n” sour: the impact of differential glycosylation on T cell responses. Nat Immunol. 2002;3:903–10. doi:10.1038/ni1002-903.
   PubMed Web of Science ®Google Scholar
• Demetriou M, Granovsky M, Quaggin S, Dennis JW. Negative regulation of T-cell activation and autoimmunity by Mgat5 N -glycosylation. Nature. 2001;409:733. doi:10.1038/35055582.
   PubMed Web of Science ®Google Scholar
• Smith LK, Boukhaled GM, Condotta SA, Mazouz S, Guthmiller JJ, Vijay R, Butler NS, Bruneau J, Shoukry NH, Krawczyk CM, et al. Interleukin-10 Directly Inhibits CD8+ T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity. Immunity. 2018;48:299–312.e5. doi:10.1016/j.immuni.2018.01.006.
   PubMed Web of Science ®Google Scholar
• An HJ, Froehlich JW, Lebrilla CB. Determination of glycosylation sites and site-specific heterogeneity in glycoproteins. Curr Opin Chem Biol. 2009;13:421–26. doi:10.1016/j.cbpa.2009.07.022.
   PubMed Web of Science ®Google Scholar
• Clark MC, Baum LG. T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival. Ann N Y Acad Sci. 2012;1253:58–67. doi:10.1111/j.1749-6632.2011.06304.x.
   PubMed Web of Science ®Google Scholar
• Golks A, Tran -T-T-T, Goetschy JF, Guerini D. Requirement for O-linked N-acetylglucosaminyltransferase in lymphocytes activation. Embo J. 2007;26:4368–79. doi:10.1038/sj.emboj.7601845.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan P, Clark PM, Mason DE, Peters EC, Hsieh-Wilson LC, Baltimore D. Activation of the Transcriptional Function of the NF-κB Protein c-Rel by O-GlcNAc Glycosylation. Sci Signal. 2013;6:ra75. doi:10.1126/scisignal.2004097.
   PubMed Web of Science ®Google Scholar
• McEver RP. Selectin-carbohydrate interactions during inflammation and metastasis. Glycoconj J. 1997;14:585–91. doi:10.1023/A:1018584425879.
   PubMed Web of Science ®Google Scholar
• Borsig L. Selectins in cancer immunity. Glycobiology. 2018;28:648–55. doi:10.1093/glycob/cwx105.
   PubMed Web of Science ®Google Scholar
• Häuselmann I, Borsig L. Altered tumor-cell glycosylation promotes metastasis. Front Oncol. 2014;4:28. doi:10.3389/fonc.2014.00028.
   PubMedGoogle Scholar
• RodrÍguez E, Schetters STT, van Kooyk Y. The tumour glyco-code as a novel immune checkpoint for immunotherapy. Nat Rev Immunol. 2018;18:204–11. doi:10.1038/nri.2018.3.
   PubMed Web of Science ®Google Scholar
• Peixoto A, Relvas-Santos M, Azevedo R, Santos LL, Ferreira JA. Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks. Front Oncol. 2019;9:380–380. doi:10.3389/fonc.2019.00380.
   PubMed Web of Science ®Google Scholar
• Li C-W, Lim S-O, Xia W, Lee -H-H, Chan L-C, Kuo C-W, Khoo K-H, Chang -S-S, Cha J-H, Kim T, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632. doi:10.1038/ncomms12632.
   PubMed Web of Science ®Google Scholar
• Li C-W, Lim S-O, Chung EM, Kim Y-S, Park AH, Yao J, Cha J-H, Xia W, Chan L-C, Kim T, et al. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell. 2018;33:187–201.e10. doi:10.1016/j.ccell.2018.01.009.
   PubMed Web of Science ®Google Scholar
• Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol. 2001;1:220–28. doi:10.1038/35105024.
   PubMed Web of Science ®Google Scholar
• Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6:1245–52. doi:10.1038/ni1271.
   PubMed Web of Science ®Google Scholar
• Wang H, Kaur G, Sankin AI, Chen F, Guan F, Zang X. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. J Hematol OncolJ Hematol Oncol. 2019;12:59. doi:10.1186/s13045-019-0746-1.
   PubMed Web of Science ®Google Scholar
• Sundblad V, Morosi LG, Geffner JR, Rabinovich GA. Galectin-1: A Jack-of-All-Trades in the Resolution of Acute and Chronic Inflammation. J Immunol. 2017;199:3721–30. doi:10.4049/jimmunol.1701172.
   PubMed Web of Science ®Google Scholar
• Clemente T, Vieira NJ, Cerliani JP, Adrain C, Luthi A, Dominguez MR, Yon M, Barrence FC, Riul TB, Cummings RD, et al. Proteomic and functional analysis identifies galectin-1 as a novel regulatory component of the cytotoxic granule machinery. Cell Death Dis. 2017;8:e3176. doi:10.1038/cddis.2017.506.
   PubMed Web of Science ®Google Scholar
• Yu F, Finley RL, Raz A, Kim H-RC. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem. 2002;277:15819–27. doi:10.1074/jbc.M200154200.
   PubMed Web of Science ®Google Scholar
• Kouo T, Huang L, Pucsek AB, Cao M, Solt S, Armstrong T, Jaffee E. Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells. Cancer Immunol Res. 2015;3:412–23. doi:10.1158/2326-6066.CIR-14-0150.
   PubMed Web of Science ®Google Scholar
• Stillman BN, Hsu DK, Pang M, Brewer CF, Johnson P, Liu F-T, Baum LG. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol Baltim Md 1950. 2006;176:778–89.
   Google Scholar
• Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother CII. 2010;59:1593–600. doi:10.1007/s00262-010-0855-8.
   PubMed Web of Science ®Google Scholar
• Lafouresse F, Bellard E, Laurent C, Moussion C, J-J F, Ysebaert L, Girard J-P. L-selectin controls trafficking of chronic lymphocytic leukemia cells in lymph node high endothelial venules in vivo. Blood. 2015;126:1336–45. doi:10.1182/blood-2015-02-626291.
   PubMed Web of Science ®Google Scholar
• Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von GS, Tzankov A, Tietze L, Lardinois D, Heinzelmann-Schwarz V, et al. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J Clin Invest. 2018;128:4912–23. doi:10.1172/JCI120612.
   PubMed Web of Science ®Google Scholar
• Haas Q, Boligan KF, Jandus C, Schneider C, Simillion C, Stanczak MA, Haubitz M, Jafari SMS, Zippelius A, Baerlocher GM, et al. Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment. Cancer Immunol Res. 2019;7:707–18. doi:10.1158/2326-6066.CIR-18-0505.
   PubMed Web of Science ®Google Scholar
• Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019;25:656–66. doi:10.1038/s41591-019-0374-x.
   PubMed Web of Science ®Google Scholar
• Limagne E, Richard C, Thibaudin M, Fumet J-D, Truntzer C, Lagrange A, Favier L, Coudert B, Ghiringhelli F. Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. Oncoimmunology. 2019;8:e1564505. doi:10.1080/2162402X.2018.1564505.
   PubMed Web of Science ®Google Scholar
• Gonçalves Silva I, Yasinska IM, Sakhnevych SS, Fiedler W, Wellbrock J, Bardelli M, Varani L, Hussain R, Siligardi G, Ceccone G, et al. The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells. EBioMedicine. 2017;22:44–57. doi:10.1016/j.ebiom.2017.07.018.
   PubMed Web of Science ®Google Scholar
• Wdowiak K, Gallego-Colon E, Francuz T, Czajka-Francuz P, Ruiz-Agamez N, Kubeczko M, Grochoła I, Wybraniec MT, Chudek J, Wojnar J. Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia. Oncol Lett. 2019;17:1019–29. doi:10.3892/ol.2018.9656.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Feng W, Wang Y-J, Sun Y, Shi G, Yu Q. Galectins as potential emerging key targets in different types of leukemia. Eur J Pharmacol. 2019;844:73–78. doi:10.1016/j.ejphar.2018.11.019.
   PubMed Web of Science ®Google Scholar
• Zhu J, Zheng Y, Zhang H, Liu Y, Sun H, Zhang P. Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway. Am J Transl Res. 2019;11:3862–78.
   PubMed Web of Science ®Google Scholar
• Goud NS, Soukya PSL, Ghouse M, Komal D, Alvala R, Alvala M. Human Galectin-1 and its inhibitors: privileged target for cancer and HIV. Mini Rev Med Chem. 2019;19:1369–78. doi:10.2174/1389557519666190304120821.
   PubMed Web of Science ®Google Scholar
• Chen H-Y, Fermin A, Vardhana S, Weng I-C, Lo KFR, Chang E-Y, Maverakis E, Yang R-Y, Hsu DK, Dustin ML, et al. Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse. Proc Natl Acad Sci U S A. 2009;106:14496–501. doi:10.1073/pnas.0903497106.
   PubMed Web of Science ®Google Scholar
• Kaur M, Kumar D, Butty V, Singh S, Esteban A, Fink GR, Ploegh HL, Sehrawat S. Galectin-3 Regulates γ-Herpesvirus Specific CD8 T Cell Immunity. iScience. 2018;9:101–19. doi:10.1016/j.isci.2018.10.013.
   PubMed Web of Science ®Google Scholar
• Polonskaya Z, Deng S, Sarkar A, Kain L, Comellas-Aragones M, McKay CS, Kaczanowska K, Holt M, McBride R, Palomo V, et al. T cells control the generation of nanomolar-affinity anti-glycan antibodies. J Clin Invest. 2017;127:1491–504. doi:10.1172/JCI91192.
   PubMed Web of Science ®Google Scholar
• Li RE, van Vliet SJ, van Kooyk Y. Using the glycan toolbox for pathogenic interventions and glycan immunotherapy. Curr Opin Biotechnol. 2018;51:24–31. doi:10.1016/j.copbio.2017.11.003.
   PubMed Web of Science ®Google Scholar
• Danishefsky SJ, Shue Y-K, Chang MN, Wong C-H. Development of Globo-H cancer vaccine. Acc Chem Res. 2015;48:643–52. doi:10.1021/ar5004187.
   PubMed Web of Science ®Google Scholar
• Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects - Tabular View - ClinicalTrials.gov; https://clinicaltrials.gov/ct2/show/record/NCT02310464
   Google Scholar
• Steentoft C, Migliorini D, King TR, Mandel U, June CH, Posey AD. Glycan-directed CAR-T cells. Glycobiology. 2018;28:656–69. doi:10.1093/glycob/cwy008.
   PubMed Web of Science ®Google Scholar
• Mereiter S, Balmaña M, Campos D, Gomes J, Reis CA. Glycosylation in the Era of Cancer-Targeted Therapy: where Are We Heading?. Cancer Cell. 2019;36:6–16. doi:10.1016/j.ccell.2019.06.006.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, D’Haens G, Pintér T, Lim R, Bodoky G, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17. doi:10.1056/NEJMoa0805019.
   PubMed Web of Science ®Google Scholar
• Lee HT, Lee SH, Heo Y-S. Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. Molecules. 2019;24:1190.
   Google Scholar
• Munkley J, Scott E. Targeting Aberrant Sialylation to Treat Cancer. Medicines. 2019;6:102. doi:10.3390/medicines6040102.
   Google Scholar
• Fraschilla I, Pillai S. Viewing Siglecs through the lens of tumor immunology. Immunol Rev. 2017;276:178–91. doi:10.1111/imr.2017.276.issue-1.
   PubMed Web of Science ®Google Scholar
• A safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors - Full Text View - clinicalTrials.gov [Internet]; [accessed 2019 Sep 18]. https://clinicaltrials.gov/ct2/show/NCT03665285
   Google Scholar
• Ren X. Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle. Cancer Biol Med. 2019;16:205–10. doi:10.20892/j.issn.2095-3941.2018.0141.
   PubMed Web of Science ®Google Scholar
• Natoni A, Macauley MS, O’Dwyer ME. Targeting Selectins and Their Ligands in Cancer. Front Oncol. 2016;6:93. doi:10.3389/fonc.2016.00093.
   PubMed Web of Science ®Google Scholar
• Chou F-C, Chen H-Y, Kuo -C-C, Sytwu H-K. Role of Galectins in Tumors and in Clinical Immunotherapy. Int J Mol Sci. 2018;19. doi:10.3390/ijms19020430.
   Web of Science ®Google Scholar
• He Y, Cao J, Zhao C, Li X, Zhou C, Hirsch FR. TIM-3, a promising target for cancer immunotherapy. Onco Targets Ther. 2018;11:7005–09. doi:10.2147/OTT.
   PubMed Web of Science ®Google Scholar
• Van Landuyt L, Lonigro C, Meuris L, Callewaert N. Customized protein glycosylation to improve biopharmaceutical function and targeting. Curr Opin Biotechnol. 2019;60:17–28. doi:10.1016/j.copbio.2018.11.017.
   PubMed Web of Science ®Google Scholar
• Buettner MJ, Shah SR, Saeui CT, Ariss R, Yarema KJ. Improving Immunotherapy Through Glycodesign. Front Immunol. 2018;9:2485.
   PubMed Web of Science ®Google Scholar
• Nemudryi AA, Valetdinova KR, Medvedev SP, Zakian SM. TALEN and CRISPR/Cas Genome Editing Systems: tools of Discovery. Acta Naturae. 2014;6:19–40. doi:10.32607/20758251-2014-6-3-19-40.
   PubMed Web of Science ®Google Scholar
• Gupta RM, Musunuru K. Expanding the genetic editing tool kit: zFNs, TALENs, and CRISPR-Cas9. J Clin Invest. 2014;124:4154–61. doi:10.1172/JCI72992.
   PubMed Web of Science ®Google Scholar
• Komor AC, Badran AH, Liu DR. CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes. Cell. 2017;169:559. doi:10.1016/j.cell.2017.04.005.
   PubMed Web of Science ®Google Scholar
• Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, Chen PJ, Wilson C, Newby GA, Raguram A, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149–57. doi:10.1038/s41586-019-1711-4.
   Google Scholar
• Kuball J, Hauptrock B, Malina V, Antunes E, Voss R-H, Wolfl M, Strong R, Theobald M, Greenberg PD. Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J Exp Med. 2009;206:463–75. doi:10.1084/jem.20082487.
   PubMed Web of Science ®Google Scholar
• Okada M, Chikuma S, Kondo T, Hibino S, Machiyama H, Yokosuka T, Nakano M, Yoshimura A. Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells. Cell Rep. 2017;20:1017–28. doi:10.1016/j.celrep.2017.07.027.
   PubMed Web of Science ®Google Scholar
• Cedeno-Laurent F, Opperman M, Barthel SR, Hays D, Schatton T, Zhan Q, He X, Matta KL, Supko JG, Frank MH, et al. Metabolic inhibition of galectin-1-binding carbohydrates accentuates anti-tumor immunity. J Invest Dermatol. 2012;132:410–20. doi:10.1038/jid.2011.335.
   PubMed Web of Science ®Google Scholar
• Ito K, Scott SA, Cutler S, Dong L-F, Neuzil J, Blanchard H, Ralph SJ. Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis. 2011;14:293–307. doi:10.1007/s10456-011-9213-5.
   PubMed Web of Science ®Google Scholar
• Rillahan CD, Antonopoulos A, Lefort CT, Sonon R, Azadi P, Ley K, Dell A, Haslam SM, Paulson JC. Global Metabolic Inhibitors of Sialyl- and Fucosyltransferases. Nat Chem Biol. 2012;8:661–68. doi:10.1038/nchembio.999.
   PubMed Web of Science ®Google Scholar
• Büll C, Boltje TJ, Balneger N, Weischer SM, Wassink M, Gemst JJV, Bloemendal VRLJ, Boon L, Vlag JVD, Heise T, et al. Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity. Cancer Res. 2018;78:3574–88. doi:10.1158/0008-5472.CAN-17-3376.
   PubMed Web of Science ®Google Scholar
• Dias AM, Correia A, Pereira MS, Almeida CR, Alves I, Pinto V, Catarino TA, Mendes N, Leander M, Oliva-Teles MT, et al. Metabolic control of T cell immune response through glycans in inflammatory bowel disease. Proc Natl Acad Sci. 2018; 115:E4651–60. doi:10.1073/pnas.1720409115.
   Google Scholar
• Zheng T, Jiang H, Gros M, Del Amo DS, Sundaram S, Lauvau G, Marlow F, Liu Y, Stanley P, Wu P. Tracking N-acetyllactosamine on cell-surface glycans in vivo. Angew Chem Int Ed Engl. 2011;50:4113–18. doi:10.1002/anie.v50.18.
   PubMed Web of Science ®Google Scholar
• Li J, Chen M, Liu Z, Zhang L, Felding BH, Moremen KW, Lauvau G, Abadier M, Ley K, Wu P. A Single-Step Chemoenzymatic Reaction for the Construction of Antibody-Cell Conjugates. ACS Cent Sci. 2018;4:1633–41. doi:10.1021/acscentsci.8b00552.
   PubMed Web of Science ®Google Scholar
• Parmar S, Liu X, Najjar A, Shah N, Yang H, Yvon E, Rezvani K, McNiece I, Zweidler-McKay P, Miller L, et al. Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo. Blood. 2015;125:1502–06. doi:10.1182/blood-2014-10-603449.
   PubMed Web of Science ®Google Scholar
• Cabral J, Hanley SA, Gerlach JQ, O’Leary N, Cunningham S, Ritter T, Ceredig R, Joshi L, Griffin MD. Distinctive Surface Glycosylation Patterns Associated With Mouse and Human CD4+ Regulatory T Cells and Their Suppressive Function. Front Immunol. 2017;8:987. doi:10.3389/fimmu.2017.00987.
   PubMed Web of Science ®Google Scholar
• Sadighi Akha AA, Berger SB, Miller RA. Enhancement of CD8 T-cell function through modifying surface glycoproteins in young and old mice. Immunology. 2006;119:187–94. doi:10.1111/imm.2006.119.issue-2.
   PubMed Web of Science ®Google Scholar
• Yoon HY, Koo H, Kim K, Kwon IC. Molecular imaging based on metabolic glycoengineering and bioorthogonal click chemistry. Biomaterials. 2017;132:28–36. doi:10.1016/j.biomaterials.2017.04.003.
   PubMed Web of Science ®Google Scholar
• Büll C, Boltje TJ, Wassink M, de Graaf AMA, van Delft FL, den Brok MH, Adema GJ. Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth. Mol Cancer Ther. 2013;12:1935–46. doi:10.1158/1535-7163.MCT-13-0279.
   PubMed Web of Science ®Google Scholar
• Varki A, Gagneux P. Multifarious roles of sialic acids in immunity. Ann N Y Acad Sci. 2012;1253:16–36. doi:10.1111/j.1749-6632.2012.06517.x.
   PubMed Web of Science ®Google Scholar
• Büll C, Heise T, van Hilten N, Pijnenborg JFA, Bloemendal VRLJ, Gerrits L, Kers-Rebel ED, Ritschel T, den Brok MH, Adema GJ, et al. Steering Siglec-Sialic Acid Interactions on Living Cells using Bioorthogonal Chemistry. Angew Chem Int Ed Engl. 2017;56:3309–13. doi:10.1002/anie.201612193.
   PubMed Web of Science ®Google Scholar
• Pan H, Li P, Li G, Li W, Hu B, He H, Chen Z, Wang F, Liu L, Gong Y, et al. Glycometabolic Bioorthogonal Chemistry‐Guided Viral Transduction for Robust Human T Cell Engineering. Adv Funct Mater. 2019;29:1807528. doi:10.1002/adfm.v29.22.
   Web of Science ®Google Scholar
• Hong S, Shi Y, Wu NC, Grande G, Douthit L, Wang H, Zhou W, Sharpless KB, Wilson IA, Xie J, et al. Bacterial glycosyltransferase-mediated cell-surface chemoenzymatic glycan modification. Nat Commun. 2019;10:1–11. doi:10.1038/s41467-019-09608-w.
   PubMed Web of Science ®Google Scholar
• Mondal N, Silva M, Castano AP, Maus MV, Sackstein R. Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding. J Biol Chem. 2019;294:18465–74. doi:10.1074/jbc.RA119.011134.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–30. doi:10.1038/nature21349.
   PubMed Web of Science ®Google Scholar